Tomorrow’s Cures. Developed. Delivered.
Leading Cell Therapy CDMO Bringing Discoveries to Life, from Early Development to Commercial Supply
Leading Cell Therapy CDMO Bringing Discoveries to Life, from Early Development to Commercial Supply

Who We Are
Delivering reliable, right-first-time manufacturing from early clinical to commercial launch. By combining deep scientific expertise with personalized service and purpose-built U.S. facilities, we act as a transparent extension of your team to ensure scalable, high-quality supply.

CDMO Services
Charting and executing full lifecycle CMC roadmaps and process development strategies that drive control, scalability, and regulatory success.

Phase-appropriate platform methods, custom-developed and validated methods, in-process testing, tracking, and trending ensure safety, potency, and consistency.

Expert release testing and characterization ensure safety and potency, building a foundation for quality and regulatory success.

Integrated early- and late-phase process development to optimize performance, control variability, and enable regulatory-ready manufacturing.

Reliable, PAI-ready everyday GMP manufacturing from early clinical through commercial supply, ensuring consistent, patient-ready cell therapy production.

Kincell Bio executes seamless tech transfers using risk-based planning, cross-functional expertise, and phase-appropriate quality controls.

Full Lifecycle Support
Kincell accelerates early-phase cell therapy programs through risk-managed CMC roadmaps, DoE-driven process optimization, and phase-appropriate analytics, aligning rapid IND readiness with long-term commercial strategy to deliver clinical material efficiently and confidently.

We advance late-phase cell therapy programs with strengthened control strategies, process characterization, and comparability planning, aligning analytical rigor, manufacturing scalability, and regulatory readiness to support pivotal studies, BLA preparation, and a confident transition toward commercial supply.

Our cell therapy CDMO solutions support commercialization with inspection-ready GMP operations, scalable manufacturing platforms, validated analytical control strategies, and supply chain resilience, ensuring reliable, cost-conscious commercial supply that meets rising regulatory expectations and delivers consistent, patient-ready cell therapy products.



Explore Kincell’s latest news and expert insights, and catch up with us at upcoming industry events.
For cell therapy programs approaching commercialization, a CDMO’s infrastructure can make or break their timeline. Hear from Kincell Bio’s leadership team on...
Kincell Bio announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T...

Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields